Skip to main content
letter
. 2009 Aug;31(4):468–470. doi: 10.1111/j.1751-553X.2008.01034.x

Figure 1.

Figure 1

Time course of HCV-RNA load and HCV-antibody titer. (a) HCV-RNA load was elevated after treatment with rituximab or a chemotherapy regimen containing rituximab. (b) HCV-RNA load was elevated and HCV-antibody titer was decreased after rituximab and CHO. (c) HCV-RNA load was elevated after rituximab-containing regimen and decreased after chemotherapy without rituximab. HCV-antibody titer was decreased after rituximab-containing regimen. (d) HCV-RNA load was elevated after rituximab-containing regimen.